Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Anaptysbio (ANAB) over the last 12 years, with Q3 2025 value amounting to $249.0 million.

  • Anaptysbio's Cash & Current Investments fell 4211.9% to $249.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $249.0 million, marking a year-over-year decrease of 4211.9%. This contributed to the annual value of $385.4 million for FY2024, which is 141.49% down from last year.
  • According to the latest figures from Q3 2025, Anaptysbio's Cash & Current Investments is $249.0 million, which was down 4211.9% from $265.7 million recorded in Q2 2025.
  • In the past 5 years, Anaptysbio's Cash & Current Investments registered a high of $548.1 million during Q4 2021, and its lowest value of $249.0 million during Q3 2025.
  • Moreover, its 5-year median value for Cash & Current Investments was $390.9 million (2023), whereas its average is $398.2 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first skyrocketed by 3923.35% in 2021, then tumbled by 4211.9% in 2025.
  • Over the past 5 years, Anaptysbio's Cash & Current Investments (Quarter) stood at $548.1 million in 2021, then dropped by 19.5% to $441.2 million in 2022, then decreased by 11.41% to $390.9 million in 2023, then dropped by 1.41% to $385.4 million in 2024, then tumbled by 35.4% to $249.0 million in 2025.
  • Its last three reported values are $249.0 million in Q3 2025, $265.7 million for Q2 2025, and $339.9 million during Q1 2025.